New cancer clinical trial: S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Published on: January 26, 2018 at 12:00PM
Conditions:   Metastatic Breast Cancer;   Metastatic Triple Negative Breast Cancer
Interventions:   Drug: Combination therapy (S81694 + paclitaxel) phase I;   Drug: Paclitaxel;   Drug: Combination therapy (S81694 + paclitaxel) phase II
Sponsors:   Institut de Recherches Internationales Servier;   ADIR Association
Recruiting
http://ift.tt/2GkQSQV